5 reports

  • SEP 07, 2017: IOVANCE BIOTHERAPEUTICS ENTERS INTO A RESEARCH COLLABORATION FOCUSED ON HEMATOLOGIC MALIGNANCIES WITH THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER
  • IOVANCE BIOTHERAPEUTICS INC - BUSINESS DESCRIPTION

Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities...

  • Cancer
  • United States
  • World
  • Company Financials
  • BioTherapeutics Inc.
  • Apr 18, 2017: Lion Biotechnologies Highlights Publication of New Translational Data in Science for TIL Therapy for Treatment of Cervical Cancer
  • Aug 16, 2017: Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer

Summary Iovance Biotherapeutics Inc (Iovance), formerly Lion Biotechnologies Inc is a biotechnology company that focuses on developing novel cancer immunotherapy products for treating various cancers.It develops products based on tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidate,...

  • Biotechnology
  • Biotherapeutic
  • Cancer
  • Therapy
  • BioTherapeutics Inc.
  • SILLAJEN ENTERS INTO R&D AGREEMENT WITH NATIONAL CANCER INSTITUTE
  • REGENERON PHARMA AND SILLAJEN BIOTHERAPEUTICS ENTER INTO AGREEMENT

Summary Sillajen Biotherapeutics (SillaJen), formerly SillaJen Inc is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer.The company’s pipeline product includes Pexa-Vec, an oncolytic immunotherapeutic virus which is in Phase III trial that is used for the treatment...

  • Biotherapeutic
  • Cancer
  • South Korea
  • M&A
  • BioTherapeutics Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..2), H1 2018

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Colorectal Cancer
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2017 Summary Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via...

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.